Trial Profile
A Multi-center, Open Label, Dose Titration, Exploratory Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Esaxerenone (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 14 Apr 2021 Results assessing antihypertensive effects and safety of Esaxerenone in hypertensive patients from two dose-escalation studies: CS3150A-J206 and one other study presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension
- 06 Apr 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.